Skip to main content
recep.adiyaman
Vision About Experience Education Skills Publications Tools Newsletter Updates Podcasts Blog Contact CV Subscribe
All Issues
Older Newer
Daily Signal April 27, 2026 · 10 min read

Issue #95: The transformative impact of AI-enabled AlphaFold 3: evolution, current status, and future prospects in structural biology.

Protein Design Digest #95: The transformative impact of AI-enabled AlphaFold 3: evolution, current …

Share X LinkedIn
Protein Design Daily

Building something in Protein Design?

I love collaborating on new challenges. Let's build together.

LinkedIn Email

Subscribe to Protein Design Digest

Daily curated signals from arXiv, PubMed, and BioRxiv.

Signal of the Day

The transformative impact of AI-enabled AlphaFold 3: evolution, current status, and future prospects in structural biology.

The AlphaFold (AF) initiative profoundly impacted structural biology, evidenced by its 2024 Nobel Prize. AlphaFold progressed from AF1 to AF2, which achieved near-experimental accuracy in single-chain protein folding, and then to AF3, expanding predictions to protein-ligand, protein-nucleic acid, and protein-protein complexes. This evolution led to the widespread adoption of AF tools, expanded structural coverage, and greater accessibility through the AlphaFold Database (AFDB), accelerating translational research, especially in structure-based drug discovery (SBDD) and the study of complex macromolecular assemblies. AF1 uses deep neural networks (DNNs), AF2 employs the Evoformer to model evolutionarily related sequences, and AF3 applies the Pairformer for pairwise amino acid interactions. The main differences between AF versions are architectural. Remaining challenges include predicting protein dynamics and multiple conformational states. This review first outlines AlphaFold’s architectural evolution, then explores the post-AlphaFold landscape and its global impact, discusses translational research applications, and addresses limitations and future directions. Despite challenges, AlphaFold is poised to further advance structural biology, particularly in biotechnology and medicine.

Why this matters: Critical for improving fold accuracy and reducing structural uncertainty in de novo design.

Also Worth Reading

Predicting the Mechanism of Action of Bawei Chufan Soup in Treating Teen Depression through Network Pharmacology, Molecular Docking and Molecular Dynamics Simulation.

Introduction The Bawei Chufan Soup (BWCFS) in Traditional Chinese Medicine (TCM) offers unique advantages in treating Teen Depression (TD). This study utilizes network pharmacology, molecular docking, and molecular dynamics simulations to predict the material basis and mechanism of action of the decoction. Methods The TCMSP, SwissADME, and SwissTargetPrediction databases were utilized to obtain the active ingredients and targets of the BWCFS. The GeneCards, OMIM, and Disgenet databases were used to identify disease targets, and the intersection of these sets was determined using the VENNY tool. The intersecting targets were imported into the String database for protein- protein interaction analysis and the screening of core targets. GO and KEGG enrichment analyses of the intersecting targets were conducted using the David database, and drugcomponent- target-pathway network diagrams were constructed using Cytoscape 3.10.0 software. The molecular docking models of the core components and key targets were generated using AutoDock Vina, and kinetic simulations were conducted using GROMACS 2020.3, paired with the best docking models. Results After screening, the study identified the core components of BWCFS as Baicalein, Kaempferol, Quercetin, Cerevisterol, and Cavidine, with the key targets for TD being AKT1, IL6, TNF, ESR1, and IL1B. GO enrichment analysis revealed that BWCFS may affect signal transduction in the treatment of TD, and is associated with cellular components such as the plasma membrane and dendrites, as well as the regulation of protein binding. KEGG analysis suggested that the intersecting genes are primarily enriched in the cyclic adenosine monophosphate (cAMP) signaling pathway. Molecular docking results indicated that AKT1 shows good binding affinity with Baicalein, Cavidine, Kaempferol, and Quercetin, while Cerevisterol exhibits strong binding with TNF. The molecular dynamics simulations were stable and reliable. During the protein-ligand complex simulation, the binding between the protein and ligand was stable, with van der Waals interactions as the primary force, while hydrogen bonds were present between both the protein and ligand. Discussion Though this study has several common limitations associated with network pharmacology, and no animal experiments have been conducted for verification, the study has successfully explored and validated the mechanism of action of BWCFS in treating TD using scientific computational methods. This study provides new perspectives and methods for the development and management of pharmacological treatments for TD, offering innovative insights into TCM approaches for its treatment. Conclusion Through network pharmacology, this study preliminarily predicted the material basis and mechanism of action of BWCFS in treating TD. Furthermore, the therapeutic effects of BWCFS on TD may be associated with neuroinflammation and structural and functional changes in neuronal dendrites. The cAMP-PKA-NF-κB and cAMP-PI3K-AKT-NF-κB pathways are proposed as potential therapeutic targets.

Identification of paucinervin D as a natural sphingosine-1-phosphate receptor 1 agonist: Insights from pharmacophore modeling, docking, molecular dynamics simulations, and density functional theory.

Sphingosine-1-phosphate receptor 1 (S1PR1), a member of the G protein-coupled receptor (GPCR) family, is a crucial therapeutic target for various diseases. Activation of S1PR1 has been recognized as an effective therapeutic strategy for multiple sclerosis (MS), inflammatory bowel disease (IBD), and psoriasis. Natural products (NPs) serve as a rich source of bioactive compounds for drug discovery. Here, we aimed to discover novel S1PR1 agonists from NPs via multi-level virtual screening (VS). Using a validated HipHop pharmacophore model, we screened a database containing 54,642 NPs, followed by molecular docking. Based on binding mode analysis, four candidate S1PR1 agonists (NPC323626, NPC264112, NPC469907, and NPC22192) were selected. Subsequent molecular dynamics (MD) simulations and binding free energy calculations confirmed the stability of the receptor-ligand complexes and their binding affinities. Among the four candidates, NPC469907 exhibited the strongest binding affinity for S1PR1, with a value of -58.08 ± 0.13 kJ/mol. Furthermore, hydrogen bonds formed between NPC469907 and Glu121 of S1PR1 were found to be essential for receptor activation. Quantum mechanical calculations further revealed that the phenyl-ring-attached hydrogen site in NPC469907 could be modified without compromising its ability to activate S1PR1. The analysis of Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) indicated that NPC469907 possessed favorable pharmacokinetic properties and low toxicity. In conclusion, our study identified NPC469907 as a promising natural S1PR1 agonist and established an effective VS strategy for the discovery of novel S1PR1 agonists.

Molecular docking approaches in mycetoma: Toward improved patient management.

Mycetoma is a neglected tropical disease characterised by chronic, granulomatous inflammation of the subcutaneous tissues, often leading to disfigurement, disability, and significant socioeconomic burdens. Caused by a diverse array of bacterial and fungal pathogens, eumycetoma is predominantly driven by Madurella mycetomatis, and current treatment strategies are limited and often ineffective. Conventional antifungal therapies, such as itraconazole, require prolonged administration, frequently combined with surgical interventions, yet cure rates remain suboptimal, and recurrence is common. The formidable protective grain, comprising microbial material, melanin, and host-derived substances, acts as a physical and biochemical barrier, impeding the penetration and efficacy of drugs. Additionally, issues such as toxicity, resistance, and high costs further complicate management, underscoring the urgent need for novel therapeutic strategies. Recent advancements in computational drug discovery, particularly molecular docking, offer promising avenues to accelerate the identification of effective anti-mycetoma agents. Molecular docking simulates the interaction between small molecules and target proteins, enabling rapid virtual screening of large compound libraries, including natural products, existing drugs, and synthetic molecules, against key pathogenic targets. This structure-based approach helps prioritise candidates with high binding affinity, guiding subsequent experimental validation and reducing both time and financial costs associated with traditional drug development. When integrated with artificial intelligence (AI) and machine learning (ML), these methods can enhance predictive accuracy, uncover novel bioactive scaffolds, and facilitate the repurposing of FDA-approved drugs such as montelukast and vilanterol. Key molecular targets in M. mycetomatis include enzymes and pathways critical for pathogen survival and virulence, notably cytochrome P450 (CYP51), dihydrofolate reductase (DHFR), chitin synthase, melanin biosynthesis pathways, and metal ion acquisition systems. Melanin production, via DHN-melanin, DOPA-melanin, and pyomelanin pathways, contributes to grain pigmentation and structural integrity, while metal ions such as iron and zinc are vital for enzymatic activities, grain formation, and fungal virulence. Disrupting metal ion homeostasis through targeting zincophores, siderophores, and zinc-binding proteins represents a promising therapeutic strategy to weaken grain robustness and enhance drug penetration. Despite the potential of molecular docking, limitations such as reliance on homology models, static protein structures, and the absence of cellular context necessitate complementary approaches, including molecular dynamics simulations and in vitro validation. These combined efforts can refine candidate compounds, optimise binding affinities, and predict pharmacokinetic properties. Furthermore, integrating docking results with clinical data and global collaboration platforms can accelerate the discovery of affordable, effective treatments tailored to endemic regions. In conclusion, leveraging molecular docking and computational methods to target essential M. mycetomatis pathways offers a promising frontier in mycetoma research. By identifying novel inhibitors and understanding pathogen biology at a molecular level, these approaches can inform targeted therapies, reduce treatment durations, and improve patient outcomes. Future research should focus on validating computational predictions experimentally and translating these findings into clinical practice, with an emphasis on accessible, cost-effective interventions for vulnerable populations affected by this neglected disease.

Research & AI Updates

From the Industry

Quick Reads

Pyrimidine Derivatives Containing a Thiosemicarbazide Moiety as Potential Antioxidant and α-Glucosidase Inhibitors: Synthesis, Bioactivity Evaluation, Molecular Docking, Molecular Dynamics Simulation, ADMET, and Drug-Likeness Studies.

In this study, a series of pyrimidine derivatives incorporating a thiosemicarbazide functional group were synthesized, and their structures were thoroughly characterized using 1 H NMR, 13 C NMR, and HRMS. Read more →

Exploring the Therapeutic Mechanism of Xiehuo Pingtu San in Treating Thyroid Eye Disease Based on Network Pharmacology, Molecular Docking, and Molecular Dynamics Simulation.

Background Xiehuo Pingtu San (XHPTS) has been shown to be safe and effective in treating thyroid eye disease (TED), yet its underlying mechanisms remain unclear. Read more →

Localized Reactivity on Protein as Riemannian Manifolds: A Geometric and Quantum-Inspired Basis for Deterministic, Metal-Aware Reactive-Site Prediction

We introduce a unified framework for analysing molecular reactivity based on a geometric, quantum-inspired environment representation and a fully deterministic, metalaware implementation. Read more →

Evaluation of plasticizer toxicity effects and mechanisms in gastric cancer based on network toxicology and molecular docking.

The hypothesized toxicity and potential molecular mechanism of gastric cancer induced by exposure of two plasticizers (DBP and DEP) were studied by network toxicology. Read more →

Structure-based design and molecular modelling of n-propylcarbazole-1,3-thiazole hybrids as potent α-glucosidase inhibitors: Kinetic, in vitro, and in vivo evaluation.

A series of seventeen novel N-propylcarbazole-1,3-thiazole derivatives (5a-5q) were synthesised via a five-step route and fully characterised by FT-IR, 1H/13C NMR, and HR-MS. Read more →

Solvatochromic, spectroscopic, DFT calculations, antimicrobial and docking studies of new Fe(III), Co(II), and Ni(II) chelates containing 1,2,4-triazine.

This study presents the synthesis and characterization of three novel metal chelates: Ni(DTHMN) (1), Co(DTHMN) (2), and Fe(DTHMN) (3). Read more →

Scaffold compound T4015 attenuates pulmonary fibrosis via suppressing JAK/STAT and NF-κB signaling.

Pulmonary fibrosis (PF) is a life-threatening interstitial lung disease characterized by scarring and inflammation in lung tissues. Read more →

Identification of an SFRP1 inhibitor as a novel therapeutic strategy for cancers using dry-wet combined drug discovery strategy

Abstract Secreted frizzled-related protein 1 (SFRP1) exerts a context-dependent dual role in cancer, and its epigenetic silencing drives pro-tumorigenic non-canonical Wnt activation, a promising therapeutic target for advanced malignancies. Read more →

Pipeline Tip

Normalise thermal B-factors when comparing different crystal structures.

Resources & Tools

Deep learning is not a magic wand, but a powerful lens for structural biology. — Recep Adiyaman

BS HF DK